Sermorelin
NeuroprotectionNeurology research on Sermorelin examines whether this truncated ghrh analogue produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: ghrh receptor agonist on pituitary somatotrophs stimulates endogenous gh release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous gh.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. Sermorelin is dosed at 200-500 mcg 1x daily subq (evening) via subq in cognitive-focused protocols, with the ~10-20 min pharmacokinetic profile shaping receptor occupancy timing.
Key Takeaways
Cognitive lens: Sermorelin acts as a modulator with both restorative and modest activating components for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: GHRH receptor agonist on pituitary somatotrophs. Neuro dose: 200-500 mcg 1x daily subq (evening) via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
GHRH receptor agonist on pituitary somatotrophs. Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH. For cognitive endpoints specifically, this mechanism translates into restorative rather than stimulant effects: reduction of neuroinflammation, support for BDNF and NGF signalling, modulation of monoamine systems, and stabilisation of cerebral perfusion. The three subsections below examine Sermorelin's CNS access route, the neurotrophic and inflammatory effects, and the receptor-level pharmacology.
Receptor pharmacology and selectivity profile
Sermorelin's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. GHRH receptor agonist on pituitary somatotrophs. Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing Sermorelin with peptides engaging the same primary receptor produces competition rather than synergy.
Central nervous system access
Sermorelin reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and ~10-20 min half-life set the timeline for CNS exposure. GHRH receptor agonist on pituitary somatotrophs. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Inflammation and neurological recovery
One of the most replicated effects across compounds in Sermorelin's class (Truncated GHRH analogue) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. Sermorelin's contribution operates on the same axis at 200-500 mcg per dose.
Where Sermorelin is used for cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Post-TBI Recovery is one of the more-reported subjective benefits of Sermorelin across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For stroke recovery, Sermorelin is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where Sermorelin is used for long-covid cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 200-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 120-500 mcg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 200-500 mcg | 1x daily SubQ (evening) |
| Maintenance phase | SubQ | 140-500 mcg | Ongoing with periodic pauses |
Dose timing for Sermorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
Sermorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- Sermorelin + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Sermorelin's mechanism in cognitive / neurological protocols.
- Sermorelin + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Sermorelin's mechanism in cognitive / neurological protocols.
- Sermorelin + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Sermorelin's mechanism in cognitive / neurological protocols.
- Sermorelin + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Sermorelin's mechanism in cognitive / neurological protocols.
Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH.
Lens-specific safety considerations for cognitive / neurological use of Sermorelin: Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Sermorelin | Truncated GHRH analogue | ~10-20 min | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Does Sermorelin cross the blood-brain barrier?
Can Sermorelin be stacked with other nootropics?
Is Sermorelin a true nootropic?
Is Sermorelin appropriate alongside SSRIs or other psychiatric medications?
How does Sermorelin's half-life affect dosing?
What route should I use for Sermorelin?
Start a Sermorelin Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified Sermorelin and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 3358 Da
- Sequence length
- 29 aa
- Half-life
- ~10-20 min
- WADA
- Banned (S2)
- FDA
- Approval withdrawn 2008 (commercial reasons); compounded prescription use widespread
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Sermorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for Sermorelin
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised